Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Sirrus's Issued Patent Portfolio Continues To Accelerate

Abstract:
Sirrus, Inc., the developer of a novel electron deficient monomer platform, is pleased to announce that it has been issued its 50th global patent, all relating to its 1,1-dicarbonyl substituted alkene monomer technology.

Sirrus's Issued Patent Portfolio Continues To Accelerate

Loveland, OH | Posted on July 18th, 2018

The company’s intellectual property portfolio includes a broad range of both composition of matter and method patents—the first of which was awarded in December 2013. “The velocity of our global patent issuances has been remarkable,” says Sirrus SVP of Technology, Jeff Sullivan. “It’s a testament to the talent and innovation of our team, creative problem solving and disruptive attributes of our technology platform.”

1,1-dicarbonyl substituted alkenes are electron deficient monomers that polymerize with very little to no energy input. Also, being disubstituted affords the ability to vary functional groups offering greater control of polymer properties.

Sirrus’s core monomer and macromer products—Chemilian™ and Forza™—have near-term applications in adhesives, sealants and coatings. Other promising applications for malonate technology are supported by the company’s intellectual property portfolio and ongoing development work with formulation partners.

The company’s key patent classes include:

Monofunctional monomer process technology – Covers commercially viable, high yield, and low-cost synthetic and process routes to monomers with a single vinyl group.

Monofunctional monomer composition of matter – Covers novel monomers providing unique polymer properties, including high Tg.

Multifunctional monomer and oligomer composition of matter – Covers novel monomers and oligomers that allow for novel crosslinking in a broad range of chemistries.

Proof of concept application and formulation – Covers novel polymerizable compositions, polymers and composites formed from Sirrus monomers.

####

About Sirrus, Inc.
Sirrus Inc. develops and supplies unique chemical building blocks for the next generation of high performance coatings, adhesives, sealants and binders. Our patented technology focuses on methylene malonates monomers and oligomeric crosslinkers that can polymerize anionically at ambient temperatures. Sirrus works with development partners in the automotive, electronics, packaging and consumer goods industries to deliver sustainable products that will enhance energy efficiency, safety and performance. Sirrus Inc. is a wholly owned subsidiary of Nippon Shokubai, a global chemical company and leading supplier of acrylates, specialty monomers, functional polymers and catalysts.

For more information, please click here

Contacts:
Mike Powers

513-448-0308

Copyright © Sirrus, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Chemistry

Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project